Making Breakthrough Discoveries
with Stealth-Body Technology
CrossPoint Therapeutics is a biotechnology company founded in October 2022. We develop new medicines on our proprietary Stealth-Body platform, designing from the outset for what the patient can tolerate as well as for what the drug can do.
We focus on refractory diseases where clinical need is high and existing options fall short — the cases where a better-tolerated treatment would change what is possible for the patient.
Think of the patient.
Follow the science.
A future where treatment gives patients back their lives, not just more time with their disease.
We design antibodies that stay silent where they shouldn’t act — so the safety we build in becomes the efficacy patients feel.
Key to the success of novel drug development
Application
Find where the technology is needed before building it.
Science
Read the data as it is.
Technology
Keep refining after it is built.
Market
Shorten the time it takes to reach the patient.
CrossPoint Therapeutics strives to develop drugs that expands the range of curable disease as well as providing dignity and better life to patients.
We will diversify our Fc inert antibody platform into various drug modalities to target indications that are challenging and in desperate need for therapeutics.
To accomplish this mission, we are always open to actively collaborate.